mRNA ratios of AR to ESR1 and PGR distinguish breast cancer subtypes based on public datasets and experimental models
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.High androgen receptor (AR) gene expression relative to estrogen receptor (ESR1) and progesterone receptor (PGR) may indicate aggressive breast cancer (BC) subtypes. These ratios could help identify BC cases with poorer prognoses.
Area Of Science
- Oncology
- Molecular Biology
- Genomics
Background
- The precise role of the androgen receptor (AR) in breast cancer (BC) pathogenesis is not fully elucidated.
- Understanding AR's influence is crucial for refining BC classification and treatment strategies.
Purpose Of The Study
- To investigate the utility of AR gene expression ratios (AR/ESR1 and AR/PGR) in differentiating BC subtypes.
- To correlate these ratios with clinical and biological features of BC.
Main Methods
- Meta-analysis of large-scale transcriptomic datasets to assess AR/ESR1 and AR/PGR ratios.
- Quantitative reverse transcription PCR (qRT-PCR) assays in BC cell lines and patient tumor tissues.
- Stratification of patient samples by estrogen receptor (ER) status.
Main Results
- Higher AR/ESR1 (≥2.0) and AR/PGR (≥1.54) ratios were linked to Luminal B and HER2-enriched BC subtypes.
- Positive AR/ESR1 and AR/PGR ratios were detected in ER-negative cell lines and ER-negative BC patient tissues.
- These findings suggest a correlation between elevated AR ratios and aggressive BC phenotypes.
Conclusions
- Elevated AR/ESR1 and AR/PGR ratios may serve as biomarkers for identifying aggressive breast cancer subtypes.
- These ratios are associated with more aggressive clinical and biological characteristics, potentially indicating a worse prognosis.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.